For comments, suggestions
Created with Raphaël 2.1.0 05.10.2016 Filing date 01.09.2020 Validation fee payment 28.02.2021 (A1) Patent application published 24.01.2025 Can request protection in MD until

Patent not validated (the request for validation was not submitted on time)


(210)Number of the EPO application20193960
(220)Filing date of the EPO application2016.10.05
(80)EPO patent specification publication (B)EPB nr. 30/2024, 2024.07.24
(110)EPO patent number3770146
(21)Number of the applicatione 2021 0108
(71)Name(s) of applicant(s), code of the countryAstellas Engineered Small Molecules US, Incorporated, US;
The Salk Institute for Biological Studies, US;
(72)Name(s) of inventor(s), code of the countryDOWNES Michael, US;
EVANS Ronald M., US;
KLUGE Arthur, US;
LAGU Bharat, US;
MIURA Masanori, JP;
PANIGRAHI Sunil Kumar, IN;
PATANE Michael, US;
SAMAJDAR Susanta, IN;
SENAIAR Ramesh, IN;
TAKAHASHI Taisuke, JP;
(73)Name(s) of owner(s), code of the countryAstellas Engineered Small Molecules US, Incorporated, US;
The Salk Institute for Biological Studies, US;
(54)Title of the inventionPPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
(13)Kind-of-document code A1
(51)International Patent Classification C07D 233/64 (2006.01.01); C07D 401/04 (2006.01.01); C07D 405/10 (2006.01.01); A61K 31/4174 (2006.01.01); A61K 31/4439 (2006.01.01); A61P 21/00 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2021.02.28
(30)Priority201562238629 P, 2015.10.07, US; 201562243263 P, 2015.10.19, US; 201662352348 P, 2016.06.20, US
Up
/Inventions/details/3770146